The Synthesis and F-18 Labeling of a Cinacalcet Analogue Based on α-(Monofluoromethyl)arylmethylamine Structure

Yongxing Lai; Jiasheng Qian; Xingjin He; Xiangsong Zhang; Jianbo Liu

doi:10.1055/s-0043-1775415

Synthesis, Table of Contents

Synthesis 2025; 57(03): 659-663
DOI: 10.1055/s-0043-1775415

paper

The Synthesis and F-18 Labeling of a Cinacalcet Analogue Based on α-(Monofluoromethyl)arylmethylamine Structure

Yongxing Lai

,

Jiasheng Qian

,

Xingjin He

,

Xiangsong Zhang

,

Jianbo Liu∗

Abstract

All articles of this category

Abstract

The fluorine-containing drug Cinacalcet is the only oral calcimimetic agent for the management of hyperparathyroidism in China and targets calcium sensitive receptor (CaSR) in organ tissues. The monofluoromethyl (CH₂F) motif, found in many drug molecules and bioactive molecules, is particularly valuable as the CH₂F functional group can mimic the methyl (CH₃) motif frequently encountered in bioactive molecules. Replacing CH₃ group of Cinacalcet with CH₂F group will both bring new opportunities for the development of Cinacalcet generic drugs and provide a new option for the F-18 labeling synthesis of Cinacalcet. A Cinacalcet analogue has been successfully synthesized using commercial 2-amino-2-(naphthalen-1-yl)ethan-1-ol and 3-(3-(trifluoromethyl)phenyl)propanal as raw materials in a total yield of 24% in five steps and achieved the F-18 labeling synthesis of this analogue. This strategy is simple and efficient, paving the way for PET imaging of CaSR related diseases and inspiring development of new drugs based on Cinacalcet.

Key words

Cinacalcet - calcimimetics - α-(monofluoromethyl)arylmethylamine - radiosynthesis - nucleophilic substitution

Full Text

References

References
1 Brown EM, MacLeod RJ. Physiol. Rev. 2001; 81: 239
2 Regard JB, Sato IT, Coughlin SR. Cell 2008; 135: 561
3 Hannan FM, Babinsky VN, Thakker RV. J. Mol. Endocrinol. 2016; 57: R127
4 Hannan FM, Thakker RV. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27: 359
5 Ward DT, Brown EM, Harris HW. J. Biol. Chem. 1998; 273: 14476
6 Tfelt-Hansen J, Brown EM. Crit. Rev. Clin. Lab. Sci. 2017; 17: 35
7 Hu J, Spiegel AM. Trends. Endocrinol. Metab. 2003; 14: 282
8 Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. Nat. Rev. Endocrinol. 2019; 15: 33
9 Hendy GN, Guarnieri V, Canaff L. Prog.Mol. Biol. Transl. Sci. 2009; 89: 31
10 Torres PU. J. Ren. Nutr. 2006; 16: 53
11 Dong BJ. Clin. Ther. 2005; 27: 1725
12 Bergström M, Långström B. Progress in Drug Research, Vol. 62 Matter A., Rudin M.; Birkhäuser: Basel, 2005
13 Deng X, Rong J, Wang L, Vasdev N, Zhang L, Josephson L, Liang SH. Angew. Chem. Int. Ed. 2019; 58: 2580
14 Pees A, Beaino W, Kooijman EJ. M, Schreurs M, Verlaan M, Schuit RC, Vosjan MJ. W. D, Engelsman AF, Windhorst AD, Vugts DJ. Nucl. Med. Biol. 2021; 102: 97
15 Liu Y, Li C, Meng J, Song D, Liu B, Xu Y. Chin. J. Org. Chem. 2020; 40: 2322
16 Shen X, Zhou M, Ni C, Zhang W, Hu J. Chem. Sci. 2014; 5: 117
17 Liu Y, Lu L, Shen Q. Angew. Chem. Int. Ed. 2017; 56: 9930
18 Senatore R, Malik M, Spreitzer M, Holzer W, Pace V. Org. Lett. 2020; 22: 1345
19 Wadoux RD. P, Lin X, Keddie NS, O’Hagan D. Tetrahedron: Asymmetry 2013; 24: 719
20 Olivito F, Costanzo P, Di Gioia ML, Nardi M, Oliverio M, Procopio A. Org. Biomol. Chem. 2018; 16: 7753
21 Schoenauer S, Buergy A, Kreissl J, Schieberle P. J. Agric. Food. Chem. 2019; 67: 2598
22 Mohammadlou A, Chakraborty A, Maday M, Yin X, Zheng L, Gholami H, Ashtekar K, Staples R, Wulff WD, Borhan B. ACS Catal. 2024; 14: 426
23 Nag S, Lehmann L, Kettschau G, Heinrich T, Thiele A, Varrone A, Gulyas B, Halldin C. Bioorgan. Med. Chem. 2012; 20: 3065
24 McConathy J, Martarello L, Malveaux EJ, Camp VM, Simpson NE, Simpson CP, Bowers GD, Olson JJ, Goodman MM. J. Med. Chem. 2002; 45: 2240

Supplementary Material

Supporting Information